Parkinsonian Disorders D020734

Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Brain Diseases » Basal Ganglia Diseases » Parkinsonian Disorders

Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Movement Disorders » Parkinsonian Disorders

Description

A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.   MeSH

Hierarchy View

Subtype Terms (3)

Lewy Body Disease
40 drugs (22 approved, 18 experimental)

Parkinson Disease
476 drugs (187 approved, 289 experimental)

Parkinson Disease, Secondary
6 approved drugs


Phase 3 Indicated Drugs (2)

Phase 1 Indicated Drugs (3)


Organization Involved with Phase 3 Indications (2)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.